~~<i id='1A09195EEA'><strike id='1A09195EEA'><tt id='1A09195EEA'><pre id='1A09195EEA'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

knowledge

author：focus 2025-09-30 00:01:10 - browse：691

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Physicians and social media: If you see something, say something?

knowledge

entertainment

knowledge

leisure time

focus

hotspot

MarionBerard/AFP/GettyImagesWiththeadventofdisease-modifyingAlzheimer’sdrugs,everyoneintheworldofAlz

WSS

UnitedHealth increases loan offers after Change Healthcare outage

Dems pitch expanding Medicare power to negotiate drug prices

Rise in cancer among younger people worries and puzzles doctors

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

'Investigate these claims': UFO transparency at center of House hearing

What to watch for from Zogenix and Amicus clinical trials

leisure time

knowledge

knowledge

Anesthesiologist group: stop taking Ozempic before surgery

Roche’s Alnylam deal shows drug firms interested in heart drugs

At least 13 dead in Texas as scorching temps continue

'Investigate these claims': UFO transparency at center of House hearing

The cancer drug shortage isn’t new — and neither are the solutions

U.K. researchers warn about biases in medical devices, algorithms

Psychedelics group wrestles with new pharma identity

Physicians and social media: If you see something, say something?

Alkermes shareholders re

Methadone treatment changes are coming. Do they go far enough?

entertainment

Stop the failed accountable care organization experiment

Argenx readies a blockbuster opportunity with drug for autoimmune disease

CVS Caremark has created a new ploy: the drug ‘rebate credit’

SCOTUS questions limit to govt efforts to fight misinformation

New Alzheimer's drugs heat up race for early detection blood tests

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

knowledge

leisure time

focus

hotspot